GlassScriptPhysician profile
Darya Soto
NPI 1982656013
$3,647.53
in general payments reported to CMS, 2019-2025
24 companies · $792 in 2025
The $792 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $77.01 · 2021: $248 · 2022: $314 · 2023: $585 · 2024: $971 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.18 |
| Education | $147.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,123.53 | 2019-2025 | Ofev, Jascayd |
| Jazz Pharmaceuticals INC. | $705.55 | 2019-2025 | Xywav |
| Inspire Medical Systems, INC. | $412.46 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $316.82 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Insmed, INC. | $284.16 | 2019-2021 | |
| United Therapeutics Corporation | $98.31 | 2023-2025 | Tyvaso, Orenitram, Tyvaso |
| Genzyme Corporation | $90.35 | 2024-2025 | |
| Resmed Corp | $77.66 | 2019-2024 | |
| Glaxosmithkline, LLC. | $64.41 | 2022-2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Itamar Medical INC | $55.18 | 2021-2025 | Watchpatone |
| Baxter Healthcare | $45.11 | 2022 | |
| Lilly USA, LLC | $44.86 | 2025 | Zepbound |
| Advanced Respiratory, INC | $39.79 | 2020-2021 | |
| Fisher & Paykel Healthcare INC | $39.73 | 2024 | Fisher & Paykel Healthcare |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $29.88 | 2024 | Lumryz |
| Merck Sharp & Dohme LLC | $28.30 | 2024 | Keytruda |
| Axsome Therapeutics, INC. | $27.04 | 2023 | Sunosi |
| Zoll Respicardia, INC. | $25.19 | 2025 | Remede System |
| Gilead Sciences, INC. | $21.97 | 2024 | |
| Noctrix Health, INC. | $20.28 | 2025 | Nidra |
| Ultragenyx Pharmaceutical INC. | $13.66 | 2020 | |
| Genentech USA, INC. | $12.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darya Soto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.